Introducing

Now Available

For your patients with Homozygous FH (HoFH)1


EVKEEZA is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL‑C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia.

Limitations of Use:

  • The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH)
  • The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined

HoFH is an ultra-rare, life-threatening disorder of lipid metabolism.2

Sign up for updates

Get information about EVKEEZA for HoFH delivered directly to your inbox.

All fields marked with * are required.

By clicking “I accept” below, I authorize Regeneron Pharmaceuticals, Inc., together with its collaborators, affiliates, representatives, agents, and contractors (collectively, “Regeneron”), to provide me with educational and promotional information, materials, and services related to HoFH disease and treatment, including EVKEEZA (evinacumab-dgnb) branded communications. I further authorize Regeneron to use my de-identified information for performing research, education, business analytics, marketing studies, or for other commercial purposes. Additionally, I understand that Regeneron may use my information (1) to help improve, develop, and evaluate products, services, materials, and programs related to my condition and treatment; and (2) as otherwise described in the Regeneron Privacy Policy. I also agree that Regeneron may contact me by mail or e-mail with information about diseases, treatments and any related information. I understand that I may opt out of these communications by e-mailing unsubscribe@regeneron.com or by sending a letter to Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, Attention: Commercial Analytics. I am at least 18 years old, and I am confirming that I have read, understand, and agree with the Regeneron Privacy Policy and Terms and Conditions.

References: 1. EVKEEZA Prescribing Information. Tarrytown, NY: Regeneron Pharmaceuticals; 2021. 2. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-2157.

IMPORTANT SAFETY INFORMATION

Contraindication

EVKEEZA™ is contraindicated in patients with a history of serious hypersensitivity reactions to evinacumab-dgnb or to any of the excipients in EVKEEZA. Serious hypersensitivity reactions, including anaphylaxis, have occurred.

Warnings and Precautions

Serious Hypersensitivity Reactions: Serious hypersensitivity reactions have occurred with EVKEEZA. If signs or symptoms of serious allergic reactions occur, discontinue EVKEEZA infusion, treat according to the standard-of-care, and monitor until signs and symptoms resolve.

Embryo-Fetal Toxicity: EVKEEZA may cause fetal harm when administered to pregnant patients. Advise patients who may become pregnant of the risk to a fetus. Consider obtaining a pregnancy test prior to initiating treatment with EVKEEZA. Advise patients who may become pregnant to use effective contraception during treatment and for at least 5 months following the last dose.

Adverse Reactions

Common adverse reactions (≥5%) were nasopharyngitis (16%), influenza-like illness (7%), dizziness (6%), rhinorrhea (5%), and nausea (5%).

Use in Specific Populations

Pregnancy: EVKEEZA may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. If a patient becomes pregnant while receiving EVKEEZA, healthcare providers should report EVKEEZA exposure by calling 1-833-385-3392.

Lactation: There are no data on the presence of evinacumab-dgnb in human milk or animal milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for EVKEEZA and any potential adverse effects on the breastfed infant from EVKEEZA or from the underlying maternal condition.

Females and Males of Reproductive Potential: Consider pregnancy testing in patients who may become pregnant prior to starting treatment with EVKEEZA. EVKEEZA may cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use effective contraception during treatment with EVKEEZA and for at least 5 months following the last dose of EVKEEZA.

Pediatrics: The safety and efficacy of EVKEEZA have not been established in pediatric patients with HoFH who are younger than 12 years old.

INDICATION

EVKEEZA is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).

Limitations of Use:

  • The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
  • The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.

Please see full Prescribing Information.